Add to Twitter
 
Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
TG4050 moves therapeutic vaccination into the digital age: combines Transgene’s expertise in viral vectors with NEC’s cutting-edge Artificial Intelligence (AI) capabilities

Novel immunotherapy is fully tailored to each individual by generating an immune response that targets highly specific patient tumor mutations

First patients enrolled in two Phase 1 trials at the Mayo Clinic and Toulouse Oncopole